Monday, November 16, 2026
  • Login
CEO North America
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
No Result
View All Result
CEO North America
No Result
View All Result

CEO NA Magazine > News > Lilly to acquire Calytrix Bio in $1.5 billion deal

Lilly to acquire Calytrix Bio in $1.5 billion deal

in News
Eli Lilly pledges $6 billion manufacturing plant in Alabama
Share on LinkedinShare on WhatsApp

Indianapolis-based pharmaceutical giant Eli Lilly announced Monday that it has agreed to acquire Calytrix Bio for up to $1.5 billion in cash to ‌expand development of treatments for rare blood cancers.

Under the terms of the agreement, Lilly will acquire Calytrix, and Calytrix shareholders could receive up to $1.5 billion in cash, inclusive of an upfront payment and subsequent payments upon the achievement of certain clinical and regulatory milestones.

Brad Prosek, President and Chief Executive Officer of Calytrix Bio, stated: “Calytrix was founded on the belief that patients with MPNs deserve therapies that do more than manage symptoms. From the beginning, our goal has been to alter the disease course in mCALR-driven ET and MF. This transaction represents an important step toward accelerating that vision. We look forward to Lilly advancing the program through the clinic and exploring its potential to benefit patients across the disease spectrum. I am deeply grateful to our team, scientific advisors, and committed investors, each of whom has supported delivery of Calytrix’s program to the starting line for clinical development.”

J.P. Morgan Life Sciences Private Capital, the life sciences venture capital arm of J.P. Morgan Asset Management, founded Calytrix in 2025.

The move is the latest in a string of acquisitions by Lilly as it works to diversify beyond its blockbuster diabetes and weight-loss franchise, the company’s primary growth engine.

Eli Lilly And Co shares rose over 1% Monday following the announcement.

By CEO NA Editorial Staff

Related Posts

Trump pardons Founder and former CEO of Binance
News

$1.2 billion in stolen Binance crypto seized by U.S.

U.S. officials order Nvidia to stop sales of AI chips to China
News

Nvidia stock continues to fall following Huang’s resignation

Microsoft outage still affecting millions of users
News

Microsoft outage still affecting millions of users

Nebius secures $3 billion deal with Meta
News

Nebius falls 10% on weak outlook

Siemens CEO says company is ready for tariffs
News

Siemens CEO vows to maintain partnership with Nvidia

Hiring Jensen Huang would be an ‘honor,’ says Musk
News

Hiring Jensen Huang would be an ‘honor,’ says Musk

Barrick CEO says copper remains on a positive trajectory despite 50% tariffs
News

Barrick Mining files for IPO of North American business

Nvidia reveals new H200 chip for AI training
News

Nvidia shares rebound 5% as Huang faces further investigation

CoreWeave and Meta sign $14 billion deal
News

CoreWeave CEO reports ‘breakout’ quarter, shares jump 11%

Mars announces $1.4 billion investment in US manufacturing
News

Mars announces $1.4 billion investment in US manufacturing

No Result
View All Result

Recent Posts

  • Lilly to acquire Calytrix Bio in $1.5 billion deal
  • Yes, the Great Barrier Reef is still a must-see
  • Why switching off from work is so hard
  • The hidden meanings in Hokusai’s iconic Great Wave
  • $1.2 billion in stolen Binance crypto seized by U.S.

Archives

Categories

  • Art & Culture
  • Business
  • CEO Interviews
  • CEO Life
  • Editor´s Choice
  • Entrepreneur
  • Environment
  • Food
  • Health
  • Highlights
  • Industry
  • Innovation
  • Issues
  • Management & Leadership
  • News
  • Opinion
  • PrimeZone
  • Printed Version
  • Technology
  • Travel
  • Uncategorized

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 2125 9933 0330

UK
Collingwood Buildings,
38 Collingwood Street,
Newcastle Upon Tyne
NE1 1JF

  • News
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life

  • CONTACT
  • GENERAL ENQUIRIES
  • ADVERTISING
  • MEDIA KIT
  • DIRECTORY
  • TERMS AND CONDITIONS

Advertising –
advertising@ceo-na.com

110 Wall St.,
3rd Floor
New York, NY.
10005
USA
+1 2125 9933 0330

UK
Collingwood Buildings,
38 Collingwood Street,
Newcastle Upon Tyne
NE1 1JF

CEO North America © 2024 - Sitemap

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • News
    • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • Opinion
  • Technology
  • Environment
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.